<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Legumain is a member of the <z:chebi fb="0" ids="22656,32664">asparaginyl</z:chebi> endopeptidase family that is over-expressed in response to hypoxic stress on <z:mp ids='MP_0001883'>mammary adenocarcinoma</z:mp>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, proliferating endothelial cells, and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-associated macrophages (TAMs) </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we demonstrate that elevated expression of legumain in <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> by a proteomic approach using isobaric tags for relative and absolute quantification (iTRAQ) followed by liquid chromatography-mass spectrometry (LC-MS/MS) </plain></SENT>
<SENT sid="2" pm="."><plain>To investigate the relationship between legumain expression and <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> development, we tested legumain expression in malignant human <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (n = 60), borderline <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (n = 20), benign <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (n = 20), and <z:mpath ids='MPATH_458'>normal</z:mpath> ovary samples (n = 20) using immunohistochemical assay (IHC) </plain></SENT>
<SENT sid="3" pm="."><plain>A correlation between legumain expression, and clinocopathologic and biological variables was also established </plain></SENT>
<SENT sid="4" pm="."><plain>Importantly, increased legumain expression was validated by real-time PCR and Western blots, correlated positively with an increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> of <z:mp ids='MP_0008000'>ovarian tumors</z:mp> (P &lt; 0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>In fact, patients with strong legumain expression had a worse prognosis (P = 0.03) </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, results of in vitro experiments revealed that over-expression of legumain correlates with increased cell migration and invasion of <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Although legumain's functional role and clinical utility remain to be established, our results indicated that a sensitive assay for early expression of legumain may serve as both a potential biomarker and a molecular target for treatment of <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> </plain></SENT>
</text></document>